Cargando…
Clinical, quality of life, and economic value of acromegaly disease control
Although acromegaly is a rare disease, the clinical, economic and health-related quality of life (HRQoL) burden is considerable due to the broad spectrum of comorbidities as well as the need for lifelong management. We performed a comprehensive literature review of the past 12 years (1998–2010) to d...
Autores principales: | Ben-Shlomo, A., Sheppard, M. C., Stephens, J. M., Pulgar, S., Melmed, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146976/ https://www.ncbi.nlm.nih.gov/pubmed/21597975 http://dx.doi.org/10.1007/s11102-011-0310-7 |
Ejemplares similares
-
Molecular targets in acromegaly
por: Labadzhyan, Artak, et al.
Publicado: (2022) -
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012) -
The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021) -
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
por: Carmichael, John D., et al.
Publicado: (2014) -
Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study
por: Giustina, Andrea, et al.
Publicado: (2019)